A variety of manifestations of demyelinating disorders are associated with anti-TNF-α therapy and include, in descending order, optic neuritis, multiple sclerosis, demyelinating neuropathy, Guillain-Barre syndrome (GBS), and transverse myelitis, all of which have a fairly low incidence [22]. The gene discussed is TNF; the disease is multiple sclerosis.